Advertisement
Advertisement
KRYS
Krystal Biotech, Inc. Common Stock
306.50
USDSponsored
+3.44
+1.14%
Nov 10, 15:59 UTC -5
Closed
After-Market
306.42
-0.08
-0.03%
Krystal Biotech, Inc. Common Stock (KRYS) Earnings
KRYS Earnings Reports
Positive Surprise Ratio
KRYS beat 22 of 37 last estimates.
59%
Next Report
Date of Next Report
Feb 15, 2027
Estimate for Q4 26 (Revenue/ EPS)
$137.50M
/$2.08
Implied change from Q3 26 (Revenue/ EPS)
+7.98%
/+1.96%
Implied change from Q4 25 (Revenue/ EPS)
+28.38%
/+22.35%
Krystal Biotech, Inc. Common Stock earnings per share and revenue
On Nov 02, 2026, KRYS reported earnings of 2.04 USD per share (EPS) for Q3 26, beating the estimate of 1.80 USD, resulting in a 13.48% surprise. Revenue reached 127.34 million, compared to an expected 128.60 million, with a -0.98% difference. The market reacted with a -10.95% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 2.08 USD, with revenue projected to reach 137.50 million USD, implying an increase of 1.96% EPS, and increase of 7.98% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Krystal Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Krystal Biotech, Inc. Common Stock reported EPS of $2.04, beating estimates by 13.48%, and revenue of $127.34M, -0.98% below expectations.
How did the market react to Krystal Biotech, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -10.95%, changed from $332.29 before the earnings release to $295.90 the day after.
When is Krystal Biotech, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 15, 2027.
What are the forecasts for Krystal Biotech, Inc. Common Stock's next earnings report?
Based on --
analysts, Krystal Biotech, Inc. Common Stock is expected to report EPS of $2.08 and revenue of $137.50M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.